KospicyKorean filings in English
Companies / Mezzion Pharma

Mezzion Pharma

(주)메지온

KOSDAQ · 140410KSIC 70113FY ends month 12Consolidated statementsMarket view
Revenue (TTM)
8.7 bn
Revenue growth
12.5%
Operating margin
-210.6%
Net margin
-340.7%
ROE
-70.4%

Quarterly results

KRW bn2024 Q42025 Q12025 Q22025 Q32025 Q42026 Q12026 Q22026 Q3
Revenue1.92.01.72.12.12.02.22.4
Operating income-4.0-3.5-3.5-4.7-5.1-4.6-4.5-4.2
Net income-11.6-3.3-1.9-5.1-24.6-5.37.7-7.4
Cash from operations––––––––
Free cash flow––––––––

Annual results

KRW bn202320242025
Revenue31.78.67.9
Operating income-14.5-14.3-16.8
Net income-12.7-19.5-34.9
Cash from operations–––
Free cash flow–––

Other ratios trailing 12 months

Gross margin-210.6%
ROA-30.0%
Liabilities / equity1.35x
Current ratio0.75x

Recent filings

FilingForm
Mon 16 Nov 2026
Quarterly Report — 2026.0910-QDART
Wed 04 Nov 2026
Material Information for Investment Decisions
투자판단관련주요경영사항 (유데나필의 호주 특허권 양도 계약 체결)
8-KDART
Thu 29 Oct 2026
Insider Ownership Report4DART